Lexicon Aims to Resubmit New Drug Application for Type 1 Diabetes Treatment Sotagliflozin to the FDA Later This Year

Resubmission plan comes amid feedback and a complete response letter issued by the FDA in 2019 for sotagliflozin in the treatment of glycemic control in type 1 diabetes patients with chronic kidney disease.

Source link
#Lexicon #Aims #Resubmit #Drug #Application #Type #Diabetes #Treatment #Sotagliflozin #FDA #Year